AtriCure ATRC 深 滬
等待開盤 10-03 09:30:00 美东时间
34.29
+0.060
+0.18%
華盛通- 最 高35.00
- 今 開34.23
- 成交量 33.28万股
- 最 低 33.92
- 昨 收 34.23
- 總市值 17.04亿
- 52周最高 43.11
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 27.32
- 委 比 49.35%
- 總股本 4970.14万
- 歷史最高 89.18
- 量 比 1.03
- 振 幅 3.16%
- 歷史最低 5.90
- 每 手 1
- 風險率 5.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多阿联酋阿布扎比AI产业高速发展，逾半数企业专注于创新与研究等
①阿布扎比的AI企业数量在2024年6月达到673家，较一年前增长61%； ②当地58%以上的AI企业专注于创新、研究与咨询； ③高速发展的核心驱动力是当地工商会以优化营商环境、政策倡导和生态互联为重点的2025-2028战略路线图。
08-12 11:31
AtriCure shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY25 guidance above estimates.
AtriCure shares are trading higher after the company reported better-than-expec...
07-30 04:19
AtriCure Q2 Adj. EPS $(0.02) Beats $(0.17) Estimate, Sales $136.139M Beat $130.171M Estimate
AtriCure (NASDAQ:ATRC) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.17) by 88.1 percent. This is a 88.24 percent increase over losses of $(0.17) per share from the same
07-30 04:04
Earnings Scheduled For July 29, 2025
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is projected to repor...
07-29 16:32
AtriCure Completes Enrollment In Left Atrial Appendage Exclusion For Prophylactic Stroke Reduction Clinical Trial
Largest cardiac surgery device trial ever with 6,500 patients enrolled, this landmark trial evaluates the stroke reduction benefit with AtriClip devices for the over one million cardiac surgery patients globally without
07-15 20:05
AtriCure’s Strong Q1: Revenue Growth and Challenges
Atricure, Inc. (($ATRC)) has held its Q1 earnings call. Read on for the main hi...
05-01 08:25
AtriCure, Inc. Reports Strong Q1 2025 Growth
Atricure, Inc. ( ($ATRC) ) has released its Q1 earnings. Here is a breakdown of...
04-30 12:25
AtriCure Earnings Preview
AtriCure (NASDAQ:ATRC) is set to give its latest quarterly earnings report on T...
04-29 03:02
美股大行评级 | 潜在涨幅686.94%！Sensei Biotherapeutics获Oppenheimer升目标价至4美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1112661771769712640.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Oppenheimer：维持Sensei Biotherapeutics(SNSE)"跑赢大市"评级，目标价从3.5美元升至4美元</p> <p>• 富国银行：上调Regulus Therapeutics(RGLS)评级至
03-29 18:13
